Yu Xin, Zhang Jianning, Liu Rui, Wang Yaming, Wang Hongwei, Wang Peng, Chen Jinhui, Liu Song
Department of Neurosurgery, Navy General Hospital, Beijing;
J Neurosurg Pediatr. 2015 May;15(5):510-8. doi: 10.3171/2014.10.PEDS14302. Epub 2015 Feb 13.
The treatment for giant posterior fossa cystic craniopharyngiomas remains an important challenge in neurosurgery. The authors evaluated the effects of treating 20 patients with giant posterior fossa cystic craniopharyngiomas using phosphorus-32 (P-32) interstitial radiotherapy at their hospital.
The patients included 11 boys and 9 girls with an age range of 3 to 168 months. Before treatment, the tumor volumes ranged from 65 to 215 ml. The intracranial pressure was increased in 16 patients, and optic nerve damage had occurred in 18. The patients received P-32 interstitial radiotherapy following stereotactic cyst-fluid aspiration or drainage and were followed up for 7-138 months.
The treatment immediately relieved the intracranial hypertension symptoms in all patients. At the end of follow-up, imaging examinations revealed that the cystic tumors had disappeared, but some residual calcification remained in 12 patients, and had decreased by more than 75% of the initial volume in 8 patients. The damaged optic nerve recovered in 3 cases, improved in 12 cases, remained unchanged in 1 case, and was aggravated in 2 cases. No other severe complications related to surgery or interstitial radiation occurred. During the follow-up period, 7 new cysts appeared in 5 patients who had received additional interstitial radiotherapies with a dose of P-32 that was calculated using the same formula as for the initial treatment. The new tumors then disappeared in 2 patients, significantly shrank in 2 patients, and progressed in 1 patient.
For treating giant posterior fossa cystic craniopharyngiomas, P-32 interstitial radiation after stereotactic cyst-fluid aspiration or drainage can achieve a high tumor control rate and has relatively satisfactory clinical effects and quality of life outcomes with few complications.
巨大后颅窝囊性颅咽管瘤的治疗仍是神经外科的一项重大挑战。作者评估了在其医院对20例巨大后颅窝囊性颅咽管瘤患者采用磷-32(P-32)间质内放疗的效果。
患者包括11名男孩和9名女孩,年龄范围为3至168个月。治疗前,肿瘤体积为65至215毫升。16例患者颅内压升高,18例出现视神经损伤。患者在立体定向囊肿液抽吸或引流后接受P-32间质内放疗,并随访7至138个月。
治疗立即缓解了所有患者的颅内高压症状。随访结束时,影像学检查显示囊性肿瘤消失,但12例患者仍有一些残留钙化,8例患者肿瘤体积较初始体积减少超过75%。3例受损视神经恢复,12例改善,1例不变,2例加重。未发生与手术或间质放疗相关的其他严重并发症。随访期间,5例接受额外间质放疗的患者出现7个新囊肿,P-32剂量使用与初始治疗相同的公式计算。2例患者新肿瘤消失,2例显著缩小,1例进展。
对于巨大后颅窝囊性颅咽管瘤的治疗,立体定向囊肿液抽吸或引流后进行P-32间质放疗可实现较高的肿瘤控制率,临床效果和生活质量结果相对满意,并发症较少。